免疫检查点抑制剂在结直肠癌中的疗效与毒性：一项真实世界回顾性分析 - Suppr

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.

作者信息

Zhou Chengjing, Jiang Ting, Li Rongzhen, Yuan Yan, Xie Weihao, Huang Xiaoxue, Wang Qiaoxuan, Chang Hui, Chen Gong, Li Yuhong, Zeng Zhifan, Xiao Weiwei, Gao Yuanhong

机构信息

Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.

Department of Colorectal Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.

出版信息

Cancer Commun (Lond). 2021 Sep;41(9):921-924. doi: 10.1002/cac2.12199. Epub 2021 Jul 30.

DOI:10.1002/cac2.12199

PMID:34327863

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8441054/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8be2/8441054/44a4ac113844/CAC2-41-921-g001.jpg

相似文献

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.

Cancer Commun (Lond). 2021 Sep;41(9):921-924. doi: 10.1002/cac2.12199. Epub 2021 Jul 30.

Primary Adrenal Insufficiency and Acute Cardiomyopathy in a Patient With Colorectal Cancer Treated With Dual Immune Checkpoint Inhibitors.

Clin Colorectal Cancer. 2021 Dec;20(4):e249-e252. doi: 10.1016/j.clcc.2021.07.002. Epub 2021 Jul 15.

Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival.

Clin Lung Cancer. 2022 Jul;23(5):e321-e324. doi: 10.1016/j.cllc.2022.05.002. Epub 2022 May 11.

Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.

JAMA Oncol. 2019 Apr 1;5(4):551-555. doi: 10.1001/jamaoncol.2018.4942.

Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.

Eur J Cancer. 2021 Mar;145:179-182. doi: 10.1016/j.ejca.2020.12.016. Epub 2021 Jan 22.

Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.

Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6.

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities.

Front Immunol. 2020 Oct 6;11:2023. doi: 10.3389/fimmu.2020.02023. eCollection 2020.

Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance.

Cancer Treat Res Commun. 2022;33:100643. doi: 10.1016/j.ctarc.2022.100643. Epub 2022 Sep 24.

Severe ototoxicity associated with immune checkpoint inhibitors (ICI) in advanced melanoma.

Eur J Cancer. 2022 Sep;173:204-206. doi: 10.1016/j.ejca.2022.06.049. Epub 2022 Jul 31.

The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.

Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.

引用本文的文献

A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation.

Signal Transduct Target Ther. 2024 Sep 2;9(1):227. doi: 10.1038/s41392-024-01939-5.

Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial.

Nat Med. 2024 Apr;30(4):1035-1043. doi: 10.1038/s41591-024-02813-1. Epub 2024 Mar 4.

Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.

Int J Biol Sci. 2024 Jan 1;20(1):137-151. doi: 10.7150/ijbs.87440. eCollection 2024.

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer.

Cancer Commun (Lond). 2023 Apr;43(4):435-454. doi: 10.1002/cac2.12412. Epub 2023 Feb 28.

LAG3-PD1 or CTLA4-PD1 Inhibition in Advanced Melanoma: Indirect Cross Comparisons of the CheckMate-067 and RELATIVITY-047 Trials.

Cancers (Basel). 2022 Oct 11;14(20):4975. doi: 10.3390/cancers14204975.

USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer.

Nat Commun. 2022 Sep 26;13(1):5644. doi: 10.1038/s41467-022-33285-x.

Epi-immunotherapy for cancers: rationales of epi-drugs in combination with immunotherapy and advances in clinical trials.

Cancer Commun (Lond). 2022 Jun;42(6):493-516. doi: 10.1002/cac2.12313. Epub 2022 Jun 1.

本文引用的文献

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699.

Germline mutational profile of Chinese patients under 70 years old with colorectal cancer.

Cancer Commun (Lond). 2020 Nov;40(11):620-632. doi: 10.1002/cac2.12093. Epub 2020 Sep 10.

Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.

Nat Med. 2020 Apr;26(4):566-576. doi: 10.1038/s41591-020-0805-8. Epub 2020 Apr 6.

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

J Clin Oncol. 2020 Jan 1;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14.

Mucinous colorectal adenocarcinoma: clinical pathology and treatment options.

Cancer Commun (Lond). 2019 Mar 29;39(1):13. doi: 10.1186/s40880-019-0361-0.

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

J Clin Oncol. 2018 Mar 10;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20.

Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

PLoS One. 2017 Dec 28;12(12):e0189848. doi: 10.1371/journal.pone.0189848. eCollection 2017.

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

Lancet Oncol. 2017 Sep;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19.

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Science. 2017 Jul 28;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real-world retrospective analysis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献